Solara Active Pharma Sciences Ltd Reports Q4 FY25 Performance with Flat YoY Revenue and Significant Improvement in Gross Margin and EBITDA

Solara Active Pharma Sciences Ltd has reported its Q4 FY25 performance in a press release for the Board Meeting held on May 15, 2025. The company's Q4 revenues were at INR 2,790 Mn with a gross margin of INR 1,605 Mn (57.5%). The Q4 EBITDA stood at INR 510 Mn (18.3%). For the FY25, the revenues were at INR 12,921 Mn, a flat YoY growth compared to INR 12,943 Mn in FY24. The gross margin improved significantly by 1,370 bps YoY to INR 6,649 Mn (51.5%). The EBITDA for FY25 was at INR 2,138 Mn (16.5%), a significant improvement by 2,360 bps YoY compared to negative INR 917 Mn (-7%) in FY24. The company experienced a challenging year due to intense competition on Ibuprofen range of products, but was able to increase gross margin and EBITDA due to its focus on margin expansion. The company has also maintained a stellar compliance track record.